HIV感染/AIDS合并结核病的临床及免疫学特点研究进展

摘要/Abstract

中图分类号:

R512.91

郭静, 沈银忠. HIV感染/AIDS合并结核病的临床及免疫学特点研究进展[J]. 诊断学理论与实践, 2021, 20(04): 401-406.

参考文献47

[1]	Jilani TN, Avula A, Zafar Gondal A, et al. Active tuberculosis[M]. StatPearls. Treasure Island (FL): StatPearls, 2020.
[2]	中华医学会感染病学分会艾滋病学组, 中华医学会热带病与寄生虫学分会艾滋病学组. HIV合并结核分枝杆菌感染诊治专家共识[J]. 中华临床感染病杂志, 2017,10(2):81-90.
[3]	World Health Organization. Global tuberculosis reports[EB/OL]. 2021-01-14[2021-03-03]. https://www.who.int/tb/publications/global_report/en/.
[4]	World Health Organization. HIV/AIDS[EB/OL]. 2021-01-14[2021-03-03]. https://www.who.int/news-room/fact-sheets/detail/hiv-aids.
[5]	中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2018版)[J]. 新发传染病电子杂志, 2019,4(2):65-84.
[6]	Bruchfeld J, Correia-Neves M, Kllenius G.Tuberculosisand HIV coinfection[J]. Cold Spring Harb Perspect Med, 2015,5(7):a017871. doi:10.1101/cshperspect.a017871 URL
[7]	World Health Organization. Tuberculosis and HIV[EB/OL]. 2021-01-14[2021-03-03]. https://www.who.int/hiv/topics/tb/en/.
[8]	Montales MT, Chaudhury A, Beebe A, et al. HIV-associated TB syndemic: a growing clinical challenge worldwide[J]. Front Public Health, 2015,3:281. doi:10.3389/fpubh.2015.00281pmid:26779470
[9]	Gupta RK, Lucas SB, Fielding KL, et al. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis[J]. AIDS, 2015,29(15):1987-2002. doi:10.1097/QAD.0000000000000802 URL
[10]	GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet,2018, 392(10159):1736-1788. doi:10.1016/S0140-6736(18)32203-7 URL
[11]	Bisson GP, Bastos M, Campbell JR, et al. Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis[J]. Lancet, 2020,396(10248):402-411. doi:10.1016/S0140-6736(20)31316-7 URL
[12]	Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Di-seases Society of America[EB/OL]. 2020-06-29[2021-08-19].
[13]	Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings[J]. Lancet Infect Dis, 2009,9(3):173-184. doi:10.1016/S1473-3099(09)70043-X URL
[14]	Rajasekaran S, Mahilmaran A, Annadurai S, et al. Manifestation of tuberculosis in patients with human immuno-deficiency virus: a large Indian study[J]. Ann Thorac Med, 2007,2(2):58-60. doi:10.4103/1817-1737.32231pmid:19727347
[15]	Méndez-Samperio P. Diagnosis of Tuberculosis in HIV Co-infected Individuals: Current Status, Challenges and Opportunities for the Future[J]. Scand J Immunol, 2017,86(2):76-82. doi:10.1111/sji.12567pmid:28513865
[16]	Manosuthi W, Wiboonchutikul S, Sungkanuparph S. Integrated therapy for HIV and tuberculosis[J]. AIDS Res Ther, 2016,13:22. doi:10.1186/s12981-016-0106-ypmid:27182275
[17]	Scott L, da Silva P, Boehme CC, et al. Diagnosis of opportunistic infections: HIV co-infections - tuberculosis[J]. Curr Opin HIV AIDS, 2017,12(2):129-138. doi:10.1097/COH.0000000000000345 URL
[18]	Denkinger CM, Schumacher SG, Boehme CC, et al. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis[J]. Eur Respir J, 2014,44(2):435-446. doi:10.1183/09031936.00007814pmid:24696113
[19]	de Siqueira-Filha NT, Legood R, Cavalcanti A, et al. Cost of Tuberculosis diagnosis and treatment in patients with HIV: a systematic literature review[J]. Value Health, 2018,21(4):482-490. doi:S1098-3015(17)33409-5pmid:29680106
[20]	Abay SM, Deribe K, Reda AA, et al. The effect of early initiation of antiretroviral therapy in TB/HIV-coinfected patients: a systematic review and meta-analysis[J]. J Int Assoc Provid AIDS Care, 2015,14(6):560-570. doi:10.1177/2325957415599210 URL
[21]	Lackner AA, Lederman MM, Rodriguez B. HIV pathogenesis: the host[J]. Cold Spring Harb Perspect Med, 2012,2(9):a007005.
[22]	Moir S, Chun TW, Fauci AS. Pathogenic mechanisms of HIV disease[J]. Annu Rev Pathol, 2011,6:223-248. doi:10.1146/annurev-pathol-011110-130254 URL
[23]	Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners[J]. J Infect Dis, 2005,191(2):150-158. pmid:15609223
[24]	Du Bruyn E, Wilkinson RJ. The immune interaction between HIV-1 Infection andMycobacteriumtuberculosis[J/OL]. Microbiol Spectr, 2016[2021-03-03]. https://pubmed.ncbi.nlm.nih.gov/28084192/.
[25]	Manabe YC, Andrade BB, Gupte N, et al. A Parsimonious host inflammatory biomarker signature predicts incident tuberculosis and mortality in advanced human immunodeficiency virus[J]. Clin Infect Dis, 2020,71(10):2645-2654. doi:10.1093/cid/ciz1147 URL
[26]	Kalsdorf B, Scriba TJ, Wood K, et al. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria[J]. Am J Respir Crit Care Med, 2009,180(12):1262-1270. doi:10.1164/rccm.200907-1011OC URL
[27]	Suarez GV, Angerami MT, Vecchione MB, et al. HIV-TB coinfection impairs CD8(+) T-cell differentiation and function while dehydroepiandrosterone improves cytotoxic antitubercular immune responses[J]. Eur J Immunol, 2015,45(9):2529-2541. doi:10.1002/eji.201545545 URL
[28]	de Martino M, Lodi L, Galli L, et al. Immune response toMycobacteriumtuberculosis: a narrative review[J]. Front Pediatr, 2019,7:350. doi:10.3389/fped.2019.00350 URL
[29]	Mancino G, Placido R, Bach S, et al. Infection of human monocytes withMycobacteriumtuberculosis enhances human immunodeficiency virus type 1 replication and transmission to T cells[J]. J Infect Dis, 1997,175(6):1531-1535. pmid:9180201
[30]	Sáez-Cirión A, Manel N. Immune responses to retroviruses[J]. Annu Rev Immunol, 2018,36:193-220. doi:10.1146/annurev-immunol-051116-052155pmid:29328787
[31]	Fenwick C, Joo V, Jacquier P, et al. T-cell exhaustion in HIV infection[J]. Annu Rev Immunol, 2018,36:193-220. doi:10.1146/annurev-immunol-051116-052155 URL
[32]	Geldmacher C, Ngwenyama N, Schuetz A, et al. Preferential infection and depletion ofMycobacteriumtuberculosis-specific CD4 T cells after HIV-1 infection[J]. J Exp Med, 2010,207(13):2869-2881. doi:10.1084/jem.20100090 URL
[33]	de Noronha AL, Báfica A, Nogueira L, et al. Lung granulomas fromMycobacteriumtuberculosis/HIV-1 co-infec-ted patients display decreased in situ TNF production[J]. Pathol Res Pract, 2008,204(3):155-161. doi:10.1016/j.prp.2007.10.008 URL
[34]	Westendorp MO, Shatrov VA, Schulze-Osthoff K, et al. HIV-1 tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state[J]. EMBO J, 1995,14(3):546-554. doi:10.1002/j.1460-2075.1995.tb07030.xpmid:7859743
[35]	Devalraju KP, Neela VSK, Ramaseri SS, et al. IL-17 and IL-22 production in HIV+ individuals with latent and active tuberculosis[J]. BMC Infect Dis, 2018,18(1):321. doi:10.1186/s12879-018-3236-0pmid:29996789
[36]	Bandaru A, Devalraju KP, Paidipally P, et al. Phosphorylated STAT3 and PD-1 regulate IL-17 production and IL-23 receptor expression inMycobacteriumtuberculosis infection[J]. Eur J Immunol, 2014,44(7):2013-2024. doi:10.1002/eji.201343680 URL
[37]	Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8⁺T cell survival in HIV infection[J]. J Exp Med, 2006,203(10):2281-2292. doi:10.1084/jem.20061496 URL
[38]	Belkaid Y, Tarbell K. Regulatory T cells in the control of host-microorganism interactions[J]. Annu Rev Immunol, 2009,27:551-589. doi:10.1146/annurev.immunol.021908.132723 URL
[39]	Kisuya J, Chemtai A, Raballah E, et al. The diagnostic accuracy of Th1(IFN-γ, TNF-α, and IL-2) and Th2 (IL-4, IL-6 and IL-10) cytokines response in AFB microscopy smear negative PTB- HIV co-infected patients[J]. Sci Rep, 2019,9(1):2966. doi:10.1038/s41598-019-39048-xpmid:30814543
[40]	Bozzano F, Marras F, de Maria A. Immunology of tuberculosis[J]. Mediterr J Hematol Infect Dis, 2014,6(1):e2014027. doi:10.4084/mjhid.2014.027 URL
[41]	Amelio P, Portevin D, Hella J, et al. HIV infection functionally impairsMycobacteriumtuberculosis-specific CD4 and CD8 T-cell responses[J]. J Virol, 2019,93(5):e01728-e01718.
[42]	赵方, 刘晓宁, 程林, 等. SOCS3及相关细胞因子在HIV/TB双重感染者血清中表达水平的研究[J]. 中华实验和临床病毒学杂志, 2017,31(6):515-518.
[43]	傅雅静, 张子宁, 刘飞鹰, 等. 我国HIV/TB双重感染者血清细胞因子水平的研究[J]. 中国医科大学学报, 2014,43(3):196-200.
[44]	Saharia KK, Petrovas C, Ferrando-Martinez S, et al. Tuberculosis therapy modifies the cytokine profile, maturation state, and expression of inhibitory molecules onMycobacteriumtuberculosis-specific CD4⁺T-cells[J]. PLoS One, 2016,11(7):e0158262. doi:10.1371/journal.pone.0158262 URL
[45]	Sutherland R, Yang H, Scriba TJ, et al. Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART[J]. AIDS, 2006,20(6):821-829. doi:10.1097/01.aids.0000218545.31716.a4pmid:16549965
[46]	Desalegn G, Tsegaye A, Gebreegziabiher D, et al. Enhanced IFN-γ, but not IL-2, response toMycobacteriumtuberculosis antigens in HIV/latent TB co-infected patients on long-term HAART[J]. BMC Immunol, 2019,20(1):35. doi:10.1186/s12865-019-0317-9pmid:31601184
[47]	Tan Q, Min R, Dai GQ, et al. Clinical and Immunological Effects of rhIL-2 Therapy in Eastern Chinese patients with multidrug-resistant tuberculosis[J]. Sci Rep, 2017,7(1):17854. doi:10.1038/s41598-017-18200-5pmid:29259310

HIV感染/AIDS合并结核病的临床及免疫学特点研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献47

相关文章15

编辑推荐

Metrics

本文评价

[1]	陈宏, 沈银忠.人类免疫缺陷病毒感染/艾滋病合并结核病的诊治进展[J]. 诊断学理论与实践, 2022, 21(04): 530-534.
[2]	汪峰, 罗颖, 孙自镛.结核病的实验诊断技术应用及流程规范化[J]. 诊断学理论与实践, 2019, 18(2): 121-126.
[3]	孟洁, 崔诗爽, 孟云霞, 王刚.2005年路易体痴呆诊断标准与2017年新版诊断标准的临床比较分析[J]. 诊断学理论与实践, 2018, 17(04): 414-418.
[4]	强琬婷, 诸江,.急性早幼粒细胞白血病小鼠模型中白血病细胞对骨髓基质细胞增殖及功能影响的研究[J]. 诊断学理论与实践, 2016, 15(01): 25-29.
[5]	卢水华,.儿童结核病诊治的新认识[J]. 诊断学理论与实践, 2015, 14(05): 397-401.
[6]	沙巍,.支气管镜介入技术在结核病诊断中的应用[J]. 诊断学理论与实践, 2015, 14(05): 407-411.
[7]	范琳,.痰涂片阴性肺结核的快速诊断认识[J]. 诊断学理论与实践, 2015, 14(05): 416-420.
[8]	肖和平, 方勇,.耐药结核病的流行现况与对策[J]. 诊断学理论与实践, 2015, 14(05): 393-396.
[9]	严福华, 李若坤,.肝脏结核的CT及MRI诊断[J]. 诊断学理论与实践, 2015, 14(05): 421-424.
[10]	张青,.干扰素γ释放试验在结核病高负担国家中的临床应用价值[J]. 诊断学理论与实践, 2015, 14(05): 412-415.
[11]	程齐俭,.综合性医院如何应对结核病防治的新挑战[J]. 诊断学理论与实践, 2015, 14(05): 402-406.
[12]	芦志英,.38例高三酰甘油血症性胰腺炎临床分析[J]. 诊断学理论与实践, 2014, 13(02): 206-207.
[13]	余红, 李春晓, 姜承易, 李玉华, 李化国, 程茹虹, 张珍, 赵东宝,.儿童皮肌炎回顾性研究——53例临床分析[J]. 诊断学理论与实践, 2014, 13(01): 49-53.
[14]	余红, 赵东宝,.儿童皮肌炎临床研究现状的认识[J]. 诊断学理论与实践, 2014, 13(01): 29-33.
[15]	何亦凡, 李惠萍,.结节病和菌阴性结核病鉴别诊断新方法的临床评价[J]. 诊断学理论与实践, 2013, 12(02): 163-165.